Author of

• 11851

  +

  P2.16 - Poster Session 2 - Other Thoracic Malignancies (ID 187)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Thymoma & Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11855

    +

    P2.16-004 - Medical management of pulmonary carcinoid tumors (ID 3416)

    09:30 - 09:30  |  Author(s): L. Sholl
    • Abstract

    Background
    The optimal medical management of pulmonary carcinoid tumors, which comprise 1-2% of all lung cancers, remains to be determined.

    Methods
    We conducted a retrospective review of patients with typical and atypical pulmonary carcinoid tumors treated at our institution between 1990-present.

    Results
    We identified 34 patients treated with chemotherapy, including 26 patients with metastatic disease (22 atypical), and 8 patients treated with adjuvant platinum-etoposide chemoradiation (6 atypical, 2 typical, 6 stage IIIA, 2 stage IIB). At an average follow-up of 12 months there were 2 recurrences in the 8 patients receiving adjuvant treatment, both of whom had atypical carcinoid (1 stage IIIA, 1 stage IIB). Of patients with metastatic disease, the principal sites of metastasis were the liver (70%), bone (40%), and brain (25%); median survival after diagnosis of metastatic disease was 3.4 years with a 5 year survival of 29%. Regimens showing efficacy in metastatic disease include octreotide (77% stable disease), etoposide-cisplatin (29% disease control, 4 partial response, 1 stable disease), and temozolomide (44% disease control, 2 partial responses, 2 stable disease).

    Conclusion
    These results support our previous finding that pulmonary carcinoid tumors are responsive to chemotherapy and that adjuvant therapy should be offered to patients with stage II or IIIA resected disease.